Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 18/20 | 0.85 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16536333 | 1.00 | LIPG (0.85) | LIPGALDH1A1L3MBTL1SMYD3 | |
| SCHEMBL16536335 | 1.00 | LIPG (0.85) | LIPGALDH1A1L3MBTL1SMYD3 | |
| SCHEMBL16536472 | 0.92 | LIPG (1.00) | LIPGALDH1A1L3MBTL1 | |
| SCHEMBL16537149 | 0.92 | LIPG (1.00) | LIPGALDH1A1L3MBTL1 | |
| SCHEMBL16536489 | 0.90 | LIPG (1.00) | LIPG | |
| SCHEMBL16535806 | 0.90 | LIPG (1.00) | LIPG | |
| SCHEMBL16536510 | 0.90 | LIPG (1.00) | LIPG | |
| SCHEMBL16536083 | 0.90 | LIPG (1.00) | LIPG | |
| SCHEMBL16536290 | 0.88 | LIPG (0.85) | LIPGALDH1A1L3MBTL1 | |
| SCHEMBL16536291 | 0.88 | LIPG (0.85) | LIPGALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2844643-B1 | PYRIMIDINEDIONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL MYERS SQUIBB CO (US) | 2016-11-30 | — | — | EP | disclosed |
| US-9199946-B2 | Pyrimidinone carboxamide inhibitors of endothelial lipase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-12-01 | — | — | US | disclosed |
| US-20150065505-A1 | PYRIMIDINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150065505-A1 | PYRIMIDINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE | LIPG, LPL, PNLIP | LIPG 1/4885ALDH1A1 410/4885L3MBTL1 3164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.